Generation and characterization of a transgenic mouse model for pancreatic cancer

World Journal of Gastroenterology

Volumn 12, Issue 17, 2006, Pages 2785-2788

  Sun, Qiang ^b   Feng, Jie ^a   Wei, Xiao Luan ^b   Zhang, Rong ^a   Dong, Su Zhen ^b   Shen, Qian ^b   Dong, Juan ^a   Li, Hou Da ^a   Hu, Ying He ^b  

^a YANGZHOU UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Animal model; Pancreatic neoplasms; SV40Tag; Transgenic mice

Indexed keywords

DNA FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENOTYPE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAMMARY GLAND; MOUSE; NONHUMAN; NORTHERN BLOTTING; OVIDUCT; PANCREAS CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

EID: 33744481309     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i17.2785     Document Type: Article

References (16)

1. Faivre J, Forman D, Esteve J, Obradovic M, Sant M. Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. Eur J Cancer 1998; 34: 2184-2190
2. Levine DS, Sanchez CA, Rabinovitch PS, Reid BJ. Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. Proc Natl Acad Sci USA 1991; 88: 6427-6431
3. Powers AC, Efrat S, Mojsov S, Spector D, Habener JF, Hanahan D. Proglucagon processing similar to normal islets in pancreatic alpha-like cell line derived from transgenic mouse tumor. Diabetes 1990; 39:406-414
4. Marton I, Johnson SE, Damjanov L Currier KS, Sundberg JP, Knowles BB. Expression and immune recognition of SV40 Tag in transgenic mice that develop metastatic osteosarcomas. Transgenic Res 2000; 9:115-125
5. Grippo PJ, Sandgren EP. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am J Pathol 2000; 157:805-813
6. Paul D, Hohne M, Pinkert C, Piasecki A, Ummelmann E, Brinster RL. Immortalized differentiated hepatocyte lines derived from transgenic mice harboring SV40 T-antigen genes. Exp Cell Res 1988; 175: 354-362
7. Dobbelstein M, Arthur AK, Dehde S, van Zee K, Dickmanns A, Fanning E. Intracistronic complementation reveals a new function of SV40 T antigen that co-operates with Rb and p53 binding to stimulate DNA synthesis in quiescent cells. Oncogene 1992; 7: 837-847
8. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, Paucha E, Livingston DM. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988; 54: 275-283
9. Wilkie TM, Schmidt RA, Baetscher M, Messing A. Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen. Oncogene 1994; 9: 2889-2895
10. Conzen SD, Cole CN. The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts. Oncogene 1995; 11: 2295-2302
11. Faas SJ, Pan S, Pinkert CA, Brinster RL, Knowles BB. Simian virus 40 (SV40)-transgenic mice that develop tumors are specifically tolerant to SV40 T antigen. J Exp Med 1987; 165: 417-427
12. Murphy D, Bishop A, Rindi G, Murphy MN, Stamp GW, Hanson J, Polak JM, Hogan B. Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary. A possible model for human multiple endocrine neoplasia type 1. Am J Pathol 1987; 129:552-566
13. Patrick TA, Kranz DM, van Dyke TA, Roy EJ. Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice. J Neurooncol 1997; 32: 111-123
14. Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 2002; 101: 224-234
15. Rattner DW, Fernandez-del Castillo C, Warshaw AL. Cystic pancreatic neoplasms. Ann Oncol 1999; 10 Suppl 4:104-106
16. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-3126